RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+20.34%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$4.16B
AUM Growth
+$4.16B
(+7.4%)
Cap. Flow
+$89.8M
Cap. Flow
% of AUM
2.16%
Top 10 Holdings %
Top 10 Hldgs %
34.47%
Holding
128
New
1
Increased
41
Reduced
25
Closed
8
Top Buys
| 1 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$42.5M |
| 2 |
Amylyx Pharmaceuticals
AMLX
|
$30.5M |
| 3 |
Baxter International
BAX
|
$20.1M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$16.5M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
$15.5M |
Top Sells
| 1 |
CVET
Covetrus, Inc. Common Stock
CVET
|
$35.1M |
| 2 |
Talphera
TLPH
|
$13.6M |
| 3 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$13.4M |
| 4 |
Arvinas
ARVN
|
$12.5M |
| 5 |
OHPAU
Orion Acquisition Corp. Unit
OHPAU
|
$9.87M |
Sector Composition
| 1 | Healthcare | 97.81% |
| 2 | Consumer Staples | 0.83% |
| 3 | Industrials | 0.36% |
| 4 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Biohaven
BHVN
$1.63B
| $9.28M | 0.22% | 668,913 +501,492 | +300% | +$6.96M |
|
77
NovoCure
NVCR
$1.38B
| $9.17M | 0.22% | 125,000 -50,000 | -29% | -$3.67M |
|
78
MacroGenics
MGNX
$112M
| $7.54M | 0.18% | 1,123,096 -83,546 | -7% | -$561K |
|
79
Disc Medicine
IRON
$2.07B
| $6.75M | 0.16% | +339,497 | New | +$6.75M |
|
|
ICVX
80
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $6.2M | 0.15% | 781,000 | – | – |
|
81
Biomea Fusion
BMEA
$116M
| $6.16M | 0.15% | 730,846 | – | – |
|
|
VIGL
82
DELISTED
Vigil Neuroscience
VIGL
| $5.9M | 0.14% | 471,958 | – | – |
|
|
NVTA
83
DELISTED
Invitae Corporation
NVTA
| $5.76M | 0.14% | 3,097,525 -289,330 | -9% | -$538K |
|
84
Pulmonx
LUNG
$69.7M
| $5.5M | 0.13% | 652,400 +55,000 | +9% | +$464K |
|
85
Novavax
NVAX
$1.21B
| $5.48M | 0.13% | 532,600 -66,700 | -11% | -$686K |
|
86
Guardant Health
GH
$8.41B
| $5.44M | 0.13% | 200,000 | – | – |
|
|
GMDA
87
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
| $5.31M | 0.13% | 4,119,883 | – | – |
|
|
FSTX
88
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
| $4.75M | 0.11% | 751,889 | – | – |
|
89
Design Therapeutics
DSGN
$315M
| $4.72M | 0.11% | 460,391 | – | – |
|
|
MREO
90
Mereo BioPharma
MREO
$272M
| $4.68M | 0.11% | 6,244,897 | – | – |
|
|
KNTE
91
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $4.56M | 0.11% | 746,973 | – | – |
|
92
Beam Therapeutics
BEAM
$1.66B
| $4.36M | 0.1% | 111,430 | – | – |
|
|
ADAP
93
Adaptimmune Therapeutics
ADAP
$15.6M
| $3.91M | 0.09% | 2,676,536 +318,992 | +14% | +$466K |
|
94
Altimmune
ALT
$338M
| $3.67M | 0.09% | 223,255 | – | – |
|
95
Xilio Therapeutics
XLO
$36.3M
| $3.67M | 0.09% | 1,362,878 | – | – |
|
|
PRTK
96
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $3.24M | 0.08% | 1,734,037 | – | – |
|
|
INZY
97
DELISTED
Inozyme Pharma
INZY
| $3.24M | 0.08% | 3,086,027 +278,409 | +10% | +$292K |
|
98
Fulcrum Therapeutics
FULC
$351M
| $2.8M | 0.07% | 384,590 | – | – |
|
|
OKUR
99
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$37.2M
| $2.66M | 0.06% | 1,143,185 | – | – |
|
100
Nkarta
NKTX
$151M
| $2.36M | 0.06% | 393,389 -222,888 | -36% | -$1.34M |
|